Improvements in patient-reported outcomes with teriflunomide: week 24 interim results from the US cohort of the Teri-PRO phase 4 study

被引：0
|
作者：
Coyle, P. K. [1 ]
LaGanke, C. [2 ]
Khatri, B. [3 ]
Edwards, K. [4 ]
Cavalier, S. [5 ]
Baldinetti, F. [5 ]
Brette, S. [6 ]
Gold, R. [7 ]
机构：
[1] SUNY Stony Brook, Stony Brook, NY 11794 USA
[2] North Cent Neurol Associates, Cullman, AL USA
[3] Wheaton Franciscan Healthcare, Reg MS Ctr, Ctr Neurol Disorders, Milwaukee, WI USA
[4] Multiple Sclerosis Ctr Northeastern New York, Latham, NY USA
[5] Genzyme, Cambridge, MA USA
[6] Lincoln, Boulogne, France
[7] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P562
引用
收藏
页码：261 / 262
页数：2
相关论文
共 50 条
  • [1] Improvements in patient-reported treatment satisfaction with teriflunomide: results from the Phase 4 Teri-PRO Study
    Coyle, P. K.
    Khatri, B.
    Edwards, K. R.
    Cavalier, S.
    Rufi, P.
    Brette, S.
    Gold, R.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 774 - 775
  • [2] Stable disability and patient-reported performance outcomes over 48 weeks of teriflunomide treatment: results from the Phase 4 Teri-PRO Study
    Gold, R.
    Khatri, B.
    Edwards, K. R.
    Cavalier, S.
    Rufi, P.
    Brette, S.
    Coyle, P. K.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 307 - 307
  • [3] Improvements in patient-reported treatment satisfaction with teriflunomide: preliminary results from the European, Latin American, and Canadian cohorts enrolled in the Teri-PRO Phase 4 Study
    Gold, R.
    Laganke, C.
    Khatri, B.
    Edwards, K.
    Cavalier, S.
    Brette, S.
    Rufi, P.
    Coyle, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 670 - 670
  • [4] Patient-Reported Outcomes (PROs) in Patients Switching to Teriflunomide From a Prior Disease-Modifying Therapy (DMT): Results From the Phase 4 Teri-PRO Study
    Coyle, Patricia K.
    Khatri, Bhupendra
    Edwards, Keith R.
    Cavalier, Steve
    Rufi, Pascal
    Brette, Sandrine
    Kulkarni, Prashant
    Gold, Ralf
    NEUROLOGY, 2017, 88
  • [5] Patient-Reported Outcomes With Teriflunomide in Patients With No Prior Disease-Modifying Therapy Use Within 2 Years: Results From the Phase 4 Teri-PRO Study
    Gold, Ralf
    Khatri, Bhupendra
    Edwards, Keith R.
    Cavalier, Steve
    Rufi, Pascal
    Brette, Sandrine
    Kulkarni, Prashant
    Coyle, Patricia K.
    NEUROLOGY, 2017, 88
  • [6] Clinical and Safety Outcomes From Patients Treated With Teriflunomide in the Phase 4 Teri-PRO Study
    Gold, Ralf
    Khatri, Bhupendra
    Edwards, Keith R.
    Lallana, Jose Meca
    Cavalier, Steve
    Rufi, Pascal
    Benamor, Myriam
    Brette, Sandrine
    Chowdhury, Somankumar
    Coyle, Patricia K.
    NEUROLOGY, 2017, 88
  • [7] Real-world treatment satisfaction with teriflunomide: results from the European cohort of the phase 4 Teri-PRO study
    Vermersch, P.
    Meca Lallana, J.
    Maida, E.
    van Pesch, V.
    Kuusisto, H.
    Comi, G.
    Johansson, R.
    Rashid, W.
    Fakas, N.
    Rufi, P.
    Poole, E.
    Gold, R.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 868 - 869
  • [8] Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study
    Coyle, Patricia K.
    Khatri, Bhupendra
    Edwards, Keith R.
    Meca-Lallana, Jose E.
    Cavalier, Steve
    Rufi, Pascal
    Benamor, Myriam
    Brette, Sandrine
    Robinson, Miqun
    Gold, Ralf
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 17 : 107 - 115
  • [9] Teriflunomide real-world safety profile: results of the Phase 4 Teri-PRO Study
    Coyle, P. K.
    Khatri, B.
    Edwards, K. R.
    Meca Lallana, J.
    Cavalier, S.
    Rufi, P.
    Benamor, M.
    Brette, S.
    Gold, R.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 308 - 309
  • [10] Teriflunomide real-world outcomes in the phase 4 Teri-PRO Study: Results from Europe, Canada, and Latin America
    Gold, R.
    Khatri, B.
    Edwards, K. R.
    Cavalier, S.
    Rufi, P.
    Thangavelu, K.
    Benamor, M.
    Coyle, P. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 197 - 197
12345